<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Cancer type considerations for COSMIC signature extraction • cancereffectsizeR</title>
<!-- favicons --><link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
<link rel="apple-touch-icon" type="image/png" sizes="180x180" href="../apple-touch-icon.png">
<link rel="apple-touch-icon" type="image/png" sizes="120x120" href="../apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" type="image/png" sizes="76x76" href="../apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" type="image/png" sizes="60x60" href="../apple-touch-icon-60x60.png">
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css">
<script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="Cancer type considerations for COSMIC signature extraction">
<meta property="og:description" content="cancereffectsizeR">
<meta property="og:image" content="/logo.png">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body data-spy="scroll" data-target="#toc">
    <div class="container template-article">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">cancereffectsizeR</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">0.1.1.9013</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="../index.html">
    <span class="fas fa fas fa-home fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="../articles/cancereffectsizeR.html">Get started</a>
</li>
<li>
  <a href="../reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Articles
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="../articles/cosmic_cancer_type_note.html">Cancer type considerations for COSMIC signature extraction</a>
    </li>
  </ul>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right">
<li>
  <a href="https://github.com/Townsend-Lab-Yale/cancereffectsizeR/">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->

      

      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1 data-toc-skip>Cancer type considerations for COSMIC signature extraction</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Townsend-Lab-Yale/cancereffectsizeR/blob/master/vignettes/cosmic_cancer_type_note.Rmd"><code>vignettes/cosmic_cancer_type_note.Rmd</code></a></small>
      <div class="hidden name"><code>cosmic_cancer_type_note.Rmd</code></div>

    </div>

    
    
<p>The <code><a href="../reference/trinuc_mutation_rates.html">trinuc_mutation_rates()</a></code> function uses mutational signature extraction to calculate relative trinucleotide-specific SNV mutation rates in tumors. The “signatures_to_remove” option allows some signatures to be excluded from this analysis, which means each tumor will receive a weight of 0 for these signatures, indicating that none of the tumor’s SNVs are attributable to these signatures. This page describes the behavior of the helper function <code><a href="../reference/suggest_cosmic_signatures_to_remove.html">suggest_cosmic_signatures_to_remove()</a></code> and the reasoning behind it.</p>
<p>In <a href="https://doi.org/10.1038/s41586-020-1943-3">Alexandrov 2020</a>, the developers of the COSMIC mutational signatures sets say that some signatures that do not appear in certain cancer types. Consider excluding some or all of these signatures in <code><a href="../reference/trinuc_mutation_rates.html">trinuc_mutation_rates()</a></code>.</p>
<p>There are also some signatures associated with various cancer treatments (SBS11, SBS31, SBS32, SBS35, SBS86, SBS87, SBS90), so you if you know that your sample is treatment-naive or hasn’t been exposed to the implicated drugs, some or all of these signatures can be excluded.</p>
<p>Note that while some COSMIC signatures are attributed to sequencing artifacts, you shouldn’t exclude these because cancereffectsizeR already handles these signatures specially.</p>
<p>The <code><a href="../reference/suggest_cosmic_signatures_to_remove.html">suggest_cosmic_signatures_to_remove()</a></code> function will identify possible signature exclusions based on cancer type and treatment status.</p>
<div class="sourceCode" id="cb1"><html><body><pre class="r">  <span class="fu"><a href="../reference/suggest_cosmic_signatures_to_remove.html">suggest_cosmic_signatures_to_remove</a></span>(<span class="kw">cancer_type</span> <span class="kw">=</span> <span class="st">"BRCA"</span>, <span class="kw">treatment_naive</span> <span class="kw">=</span> <span class="fl">TRUE</span>)
  <span class="fu"><a href="../reference/suggest_cosmic_signatures_to_remove.html">suggest_cosmic_signatures_to_remove</a></span>(<span class="kw">cancer_type</span> <span class="kw">=</span> <span class="st">"Kidney-RCC"</span>)</pre></body></html></div>
<p>The cancer type recommendations are based on Extended Data Figure 5 of Alexandrov 2020. The first two columns of the table below, also based on that figure, give the labels accepted by the <code>cancer_type</code> argument. (Note: SBS84 and SBS85 are absent from the Alexandrov figure, but they are elsewhere described in the paper as specific to lymphoid neoplasms.)</p>
<p>Before excluding signatures, make sure your data set does not contain tumors from multiple PCAWG categories. For example, TCGA HNSC (head and neck cancer) includes oral cancers, which are listed separately here as Oral-SCC, so excluding all signatures that do not appear in Head-SCC (such as SBS29, tobacco chewing) would not be appropriate.</p>
<table class="table table table-condensed">
<thead><tr>
<th style="text-align:right;">
PCAWG
</th>
<th style="text-align:right;">
Applicable_TCGA
</th>
<th style="text-align:right;">
Number_of_tumors
</th>
<th style="text-align:right;">
Description
</th>
</tr></thead>
<tbody>
<tr>
<td style="text-align:right;">
ALL
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
33
</td>
<td style="text-align:right;">
acute lymphoblastic leukemia
</td>
</tr>
<tr>
<td style="text-align:right;">
Biliary-AdenoCA
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
173
</td>
<td style="text-align:right;">
biliary adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Bladder-TCC
</td>
<td style="text-align:right;">
BLCA
</td>
<td style="text-align:right;">
369
</td>
<td style="text-align:right;">
bladder transitional cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Bone-Osteosarc
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
36
</td>
<td style="text-align:right;">
sarcoma, bone
</td>
</tr>
<tr>
<td style="text-align:right;">
Bone-Other
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
18
</td>
<td style="text-align:right;">
Paper vague; presumably bone cartilaginous neoplasm osteoblastoma, bone osteofibrous dysplasia, bone neoplasm epithelioid
</td>
</tr>
<tr>
<td style="text-align:right;">
Breast
</td>
<td style="text-align:right;">
BRCA
</td>
<td style="text-align:right;">
834
</td>
<td style="text-align:right;">
breast adenocarcinoma, ductal carcinoma in situ, breast lobular carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Cervix
</td>
<td style="text-align:right;">
CESC
</td>
<td style="text-align:right;">
204
</td>
<td style="text-align:right;">
cervical squamous cell carcinoma and adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-GBM
</td>
<td style="text-align:right;">
GBM
</td>
<td style="text-align:right;">
100
</td>
<td style="text-align:right;">
CNS glioblastoma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-LGG
</td>
<td style="text-align:right;">
LGG
</td>
<td style="text-align:right;">
27
</td>
<td style="text-align:right;">
CNS lower-grade glioma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-Medullo
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
185
</td>
<td style="text-align:right;">
CNS medulloblastoma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-Oligo
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
18
</td>
<td style="text-align:right;">
CNS oligodenroglioma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-PiloAstro
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
48
</td>
<td style="text-align:right;">
CNS pilocytic astrocytoma
</td>
</tr>
<tr>
<td style="text-align:right;">
ColoRect-AdenoCA
</td>
<td style="text-align:right;">
COAD, READ
</td>
<td style="text-align:right;">
719
</td>
<td style="text-align:right;">
colorectal adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Eso-AdenoCA
</td>
<td style="text-align:right;">
ESCA
</td>
<td style="text-align:right;">
347
</td>
<td style="text-align:right;">
esophagus adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Eso-SCC
</td>
<td style="text-align:right;">
ESCA
</td>
<td style="text-align:right;">
160
</td>
<td style="text-align:right;">
esophagus squamous cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Ewings
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
85
</td>
<td style="text-align:right;">
Ewing’s sarcoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Eye-Melanoma
</td>
<td style="text-align:right;">
UVM
</td>
<td style="text-align:right;">
13
</td>
<td style="text-align:right;">
uveal melanoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Head-SCC
</td>
<td style="text-align:right;">
HNSC
</td>
<td style="text-align:right;">
313
</td>
<td style="text-align:right;">
head-and-neck squamous cell carcinoma (note HNSC also includes some Oral-SCC)
</td>
</tr>
<tr>
<td style="text-align:right;">
Kidney-ChRCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
46
</td>
<td style="text-align:right;">
kidney chromophobe renal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Kidney-Papillary
</td>
<td style="text-align:right;">
KIRP
</td>
<td style="text-align:right;">
21
</td>
<td style="text-align:right;">
papillary renal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Kidney-RCC
</td>
<td style="text-align:right;">
KIRC
</td>
<td style="text-align:right;">
184
</td>
<td style="text-align:right;">
kidney renal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Liver-HCC
</td>
<td style="text-align:right;">
LIHC
</td>
<td style="text-align:right;">
489
</td>
<td style="text-align:right;">
liver hepatocellular carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lung-AdenoCA
</td>
<td style="text-align:right;">
LUAD
</td>
<td style="text-align:right;">
438
</td>
<td style="text-align:right;">
lung adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lung-SCC
</td>
<td style="text-align:right;">
LUSC
</td>
<td style="text-align:right;">
350
</td>
<td style="text-align:right;">
lung squamous cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lymph-BNHL
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
135
</td>
<td style="text-align:right;">
lymphoid mature B-cell lymphoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lymph-CLL
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
171
</td>
<td style="text-align:right;">
lymphoid chronic lymphocytic leukemia
</td>
</tr>
<tr>
<td style="text-align:right;">
Myeloid-AML
</td>
<td style="text-align:right;">
LAML
</td>
<td style="text-align:right;">
106
</td>
<td style="text-align:right;">
acute myeloid leukemia
</td>
</tr>
<tr>
<td style="text-align:right;">
Myeloid-MDS/MPN
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
43
</td>
<td style="text-align:right;">
myelodysplastic syndrome and myeloproliferative neoplasm
</td>
</tr>
<tr>
<td style="text-align:right;">
Oral-SCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
52
</td>
<td style="text-align:right;">
oral squamous cell carcinoma (note some TCGA HNSC are oral)
</td>
</tr>
<tr>
<td style="text-align:right;">
Ovary-AdenoCA
</td>
<td style="text-align:right;">
OV
</td>
<td style="text-align:right;">
149
</td>
<td style="text-align:right;">
ovary adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Panc-AdenoCA
</td>
<td style="text-align:right;">
PAAD
</td>
<td style="text-align:right;">
357
</td>
<td style="text-align:right;">
pancreatic adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Panc-Endocrine
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
95
</td>
<td style="text-align:right;">
pancreatic neuroendocrine tumor
</td>
</tr>
<tr>
<td style="text-align:right;">
Prost-AdenoCA
</td>
<td style="text-align:right;">
PRAD
</td>
<td style="text-align:right;">
407
</td>
<td style="text-align:right;">
prostate adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Sarcoma
</td>
<td style="text-align:right;">
SARC
</td>
<td style="text-align:right;">
26
</td>
<td style="text-align:right;">
sarcoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Sarcoma-bone
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
59
</td>
<td style="text-align:right;">
paper unclear; perhaps osteosarcoma and other sarcomas combined?
</td>
</tr>
<tr>
<td style="text-align:right;">
Skin-BCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
117
</td>
<td style="text-align:right;">
skin basal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Skin-Melanoma
</td>
<td style="text-align:right;">
SKCM
</td>
<td style="text-align:right;">
809
</td>
<td style="text-align:right;">
skin melanoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Skin-SCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
41
</td>
<td style="text-align:right;">
skin squamous cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
SoftTissue-Leiomyo
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
15
</td>
<td style="text-align:right;">
leiomyosarcoma soft tissue
</td>
</tr>
<tr>
<td style="text-align:right;">
SoftTissue-Liposarc
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
19
</td>
<td style="text-align:right;">
liposarcoma soft tissue
</td>
</tr>
<tr>
<td style="text-align:right;">
Stomach-AdenoCA
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
452
</td>
<td style="text-align:right;">
stomach adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Thy-AdenoCA
</td>
<td style="text-align:right;">
THCA
</td>
<td style="text-align:right;">
67
</td>
<td style="text-align:right;">
thyroid low-grade adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Uterus-AdenoCA
</td>
<td style="text-align:right;">
UCEC
</td>
<td style="text-align:right;">
291
</td>
<td style="text-align:right;">
uterus adenocarcinoma
</td>
</tr>
</tbody>
</table>
<div id="cosmic-3-1-update" class="section level3">
<h3 class="hasAnchor">
<a href="#cosmic-3-1-update" class="anchor"></a>COSMIC 3.1 Update</h3>
<p>The new treament-associated signatures introduced in COSMIC 3.1 in July 2020 have been added to this page. Additionally, SBS88, associated with colibactin exposure, is not in the above table, but the COSMIC signature site says that it is found in head and neck, oral, urinary tract, and colorectal cancers.</p>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">

      </div>

</div>



      <footer><div class="copyright">
  <p>Developed by Vincent L. Cannataro, Jeff Mandell.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.5.1.</p>
</div>

      </footer>
</div>

  


  </body>
</html>
